相关实验视频

Updated: Jan 8, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

深入分析突出了Efgartigimod对肌痛性硬化症内在和适应性免疫细胞的影响

Lei Jin¹, Liu Dong², Ying Wang³

¹Huashan Rare Disease Centre and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Centre for Neurological Disorders, Fudan University, Shanghai, China.

Annals of clinical and translational neurology

|December 18, 2025

概括

埃夫加尔蒂基莫德 (Efgartigimod) 是一种治疗全般性肌痛性肌痛症 (gMG) 的药物,通过减少单细胞和淋巴细胞上的FcRn表达来调节免疫细胞. 这导致免疫细胞群体的显著变化,证明了其免疫调节潜力.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
自免疫性疾病自免疫性疾病

背景情况:

骨髓灰质炎 (MG) 是一种自身免疫性疾病,涉及补体激活.
埃夫加蒂格莫德已被批准用于通用MG (gMG),但其对免疫细胞的影响尚不清楚.

研究的目的:

调查efgartigimod对gMG免疫细胞群的影响.
探索efgartigimod对先天性和适应性免疫的调节作用.

主要方法:

在gMG患者的外周免疫细胞中量化FcRn表达.
评估了efgartigimod在体外对免疫细胞的影响.
在接受efgartigimod.com治疗的现实世界gMG队列中验证了这些发现.

主要成果:

埃夫加尔蒂基莫德降低了单细胞和淋巴细胞上的FcRn表达.
下调的非经典单细胞和Th17.1细胞.
扩大了产生抗体的B细胞和T细胞 (CD4+,CD8+).

结论:

埃夫加蒂格莫德显示出显著的免疫调节作用.
调节周边免疫细胞突出了efgartigimod在gMG中的临床潜力.
这些发现结合了关于efgartigimod免疫影响的体外和临床数据.

关键词:

在Efgartigimod中使用.在FcRnnn中.一般化骨髓灰质炎 (Myasthenia Gravis) 的发生.在深入的深度.周边免疫细胞是什么?

更多相关视频

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...